Actively Recruiting
Randomized Study of Once-Weekly Berobenatide Injections vs Placebo in Adults With Obesity Disease in Japan
Led by Pfizer · Updated on 2026-10-15
180
Participants Needed
34
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of berobenatide PF-08653944 in adults with obesity disease, a condition characterized by excess body fat that can harm health and increase the risk of other medical problems. Some participants may also have type 2 diabetes, where the body does not use insulin properly, leading to high blood sugar levels. This Phase 3 clinical trial is being conducted in Japan to better understand how berobenatide works for people with these conditions. Participants will be randomly assigned to receive either berobenatide or a placebo. Both treatments are given as injections under the skin of the abdomen once a week. The study compares the effects of berobenatide to placebo in helping people lose weight and examines its safety. About 180 adults will participate, and the study includes up to 15 in-person visits and 2 phone visits over approximately 22 months. During the study, participants will have their body weight and waist circumference measured, along with blood pressure and blood tests to check glucose, insulin, cholesterol, and inflammation markers. Questionnaires about quality of life related to weight will also be completed. Researchers will monitor for any side effects or adverse events. The main outcome is the percent change in body weight from the start to week 72, with other health measures also tracked throughout the trial.
CONDITIONS
Brief Title
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here